Inflammatory Bowel Diseases: Clinical Trials

1734 completed, 639 unknown, 519 recruiting, 389 terminated. 952 Not applicable, 664 Phase 2, 459 Phase 3, 350 Phase 1, 268 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	952	Completed 382, Unknown 212, Recruiting 150, Terminated 72, Not yet recruiting 57, Active not recruiting 35, Withdrawn 29, Enrolling by invitation 9, Suspended 6
Phase 2	664	Completed 303, Terminated 135, Recruiting 88, Unknown 54, Withdrawn 33, Active not recruiting 27, Not yet recruiting 19, Enrolling by invitation 4, Suspended 1
Phase 3	459	Completed 249, Terminated 74, Unknown 46, Recruiting 40, Active not recruiting 26, Withdrawn 16, Not yet recruiting 6, Enrolling by invitation 2
Phase 1	350	Completed 192, Terminated 47, Unknown 33, Recruiting 30, Not yet recruiting 18, Withdrawn 17, Active not recruiting 9, Enrolling by invitation 3, Suspended 1
Phase 4	268	Completed 117, Unknown 43, Recruiting 33, Terminated 33, Not yet recruiting 22, Withdrawn 13, Active not recruiting 5, Enrolling by invitation 2
Early Phase 1	44	Unknown 14, Completed 8, Not yet recruiting 7, Recruiting 6, Withdrawn 4, Terminated 3, Active not recruiting 1, Enrolling by invitation 1

Follow Inflammatory Bowel Diseases: new trials by email Literature Review of Inflammatory Bowel Diseases trials Research Report on Inflammatory Bowel Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis High dose budesonide rectal foam, Low dose budesonide rectal foam, Matching placebo rectal foam - Ulcerative Colitis	Phase 4	Not yet recruiting	Bausch Health Americas, Inc.	100	2029-06-01	2026-10-06
ACT for Veterans With IBD and Mental Health Challenges Acceptance and Commitment Therapy - Inflammatory Bowel Diseases, Crohn's Disease	Not applicable	Not yet recruiting	VA Office of Research and Development	50	2028-01-01	2026-02-09
A Mindfulness-based Stress Reduction Program for IBD Mindfulness based stress reduction, Active Control - Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis)	Not applicable	Not yet recruiting	Nova Scotia Health Authority	70	2027-09-01	2026-09-08
Digital Mind Body Intervention Among Black and Hispanic Patients Living With Inflammatory Bowel Disease Digital Mind Body Intervention mobile application - Crohn's Disease, Ulcerative Colitis	Not applicable	Not yet recruiting	Montefiore Medical Center	40	2027-07-01	2026-09-14
Adapted Physical Activity for Persistent Fatigue in Patients With Inflammatory Bowel Disease in Remission Adapted Physical Activity, Usual Care - Inflammatory Bowel Diseases (IBD), Fatigue	Not applicable	Not yet recruiting	University Hospital, Grenoble	120	2027-06-01	2026-09-11
ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery 5-ASA, Placebo - Ulcerative Colitis (UC), Pouchitis	Phase 4	Not yet recruiting	University Hospital, Linkoeping	110	2027-04-01	2026-08-19
LMT503 First-in-human SAD, MAD, and FE Study LMT503, Placebo - Inflammatory Bowel Disease, Colitis, Ulcerative	Phase 1	Not yet recruiting	Lmito Therapeutics Inc.	72	2027-03-01	2026-09-01
Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH). TRA16, Placebo - Enteric Hyperoxaluria	Phase 2	Not yet recruiting	Wuhan Kangfude Urolithiasis Research Institute Co., Ltd.	30	2027-03-01	2026-10-13
Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC)	Phase 2 / Phase 3	Not yet recruiting	Tanta University	44	2027-01-01	2026-09-15
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis treatment withdrawal - Ulcerative Colitis in Remission	Phase 4	Not yet recruiting	Assistance Publique Hopitaux De Marseille	224	2027-01-01	2026-07-22
Biophysical Assessments of Acupuncture Points in Inflammatory Bowel Disease Inflammatory Bowel Disease (IBD)		Not yet recruiting	Brigham and Women's Hospital	100	2027-01-01	2026-10-20
Oral Aeromonas sp. MTB Phage Therapy for Pouchitis in Patients With Ulcerative Colitis (UC) MTB-targeted phage therapy - Pouchitis, UC - Ulcerative Colitis	Early Phase 1	Not yet recruiting	Jinling Hospital, China	12	2027-01-01	2026-10-22
Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis ATTO-1091, Placebo - Ulcerative Colitis (UC)	Phase 1	Not yet recruiting	Attovia Therapeutics Inc	96	2026-12-14	2026-09-15
Visualization of the Colon Through Use of the Magnetic Flexible Endoscope (MFE) in Participants With Inflammatory Bowel Disease (IBD) Magnetic Flexible Endoscope (MFE) - Inflammatory Bowel Disease (IBD), Colonoscopy	Not applicable	Not yet recruiting	Vanderbilt University Medical Center	6	2026-12-01	2026-08-20
The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares elemental diet (ED) - Inflammatory Bowel Disease	Not applicable	Not yet recruiting	Wake Forest University Health Sciences	42	2026-12-01	2026-09-28
IBDminds - Mapping the Influence of aNxiety and DepreSsion on IBD Questionnaire - Inflammatory Bowel Diseases, Mental Health Issue		Not yet recruiting	The Royal Wolverhampton Hospitals NHS Trust	450	2026-12-01	2026-09-15
MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease Mirikizumab, Fistula Tract Curettage and Closure - Crohn's Disease, Perianal Fistula	Phase 4	Not yet recruiting	Icahn School of Medicine at Mount Sinai	50	2026-12-01	2026-08-24
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab - Ulcerative Colitis (UC)	Phase 4	Not yet recruiting	University Hospital, Clermont-Ferrand	240	2026-12-01	2026-10-21
Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose Upadacitinib - Ulcerative Colitis (UC)	Phase 4	Not yet recruiting	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	100	2026-11-15	2026-07-31
Microbiome-targeted Diet Therapy in Ulcerative Colitis High Protein, High Fiber (HPHF) Diet - Ulcerative Colitis	Not applicable	Recruiting	University of Minnesota	40	2026-11-09	2026-10-20

Showing 20 of 3810. Sign in to see all of them.

Narrower conditions

Crohn Disease (1944)  ·  Colitis, Ulcerative (1791)  ·  Arthritis, Rheumatoid (85)  ·  Colitis (77)  ·  Irritable Bowel Syndrome (74)  ·  Colorectal Neoplasms (62)  ·  Arthritis, Psoriatic (56)  ·  Gastrointestinal Diseases (51)  ·  Psoriasis (48)  ·  Spondylitis, Ankylosing (48)  ·  Inflammation (47)  ·  Colonic Neoplasms (44)  ·  Intestinal Diseases (41)  ·  Digestive System Diseases (34)

Broader conditions

Gastroenteritis (3797)  ·  Digestive System Diseases (3776)  ·  Intestinal Diseases (3769)  ·  Gastrointestinal Diseases (3759)  ·  Colonic Diseases (1907)  ·  Colitis (1743)  ·  Pathological Conditions, Signs and Symptoms (414)  ·  Pathologic Processes (229)  ·  Immune System Diseases (171)  ·  Musculoskeletal Diseases (154)  ·  Skin and Connective Tissue Diseases (151)  ·  Neoplasms (143)  ·  Nutritional and Metabolic Diseases (138)  ·  Joint Diseases (136)

Interventions

Infliximab (140)  ·  Adalimumab (107)  ·  Mesalamine (102)  ·  vedolizumab (93)  ·  Fecal Microbiota Transplantation (70)  ·  Ustekinumab (65)  ·  Azathioprine (46)  ·  Blood Specimen Collection (39)  ·  Certolizumab Pegol (35)  ·  Colonoscopy (31)  ·  Cholecalciferol (27)  ·  Endoscopy (27)  ·  golimumab (27)  ·  mirikizumab (27)  ·  risankizumab (26)

Sponsors

Takeda (80)  ·  AbbVie (74)  ·  Assiut University (54)  ·  Pfizer (52)  ·  Janssen Research & Development, LLC (45)  ·  Sixth Affiliated Hospital, Sun Yat-sen University (40)  ·  Mayo Clinic (33)  ·  Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (30)  ·  Ferring Pharmaceuticals (29)  ·  GlaxoSmithKline (29)  ·  Assistance Publique - Hôpitaux de Paris (28)  ·  Second Affiliated Hospital of Wenzhou Medical University (27)  ·  Central Hospital, Nancy, France (26)  ·  Merck Sharp & Dohme LLC (25)  ·  Bristol-Myers Squibb (24)

Countries

United States (1205)  ·  France (522)  ·  Canada (515)  ·  Germany (423)  ·  United Kingdom (408)  ·  Italy (398)  ·  China (382)  ·  Poland (356)  ·  Belgium (355)  ·  Israel (342)  ·  Netherlands (318)  ·  Spain (312)  ·  Hungary (266)  ·  Czechia (257)  ·  Australia (242)

Top investigators

Arie Levine, MD (10)

Results publications

PMID 40243391, PMID 40357993, PMID 40013523, PMID 29380251, PMID 32445184, PMID 26893500, PMID 35648151, PMID 36124702, PMID 37368103, PMID 29850873, PMID 30476584, PMID 30739254, PMID 31077827, PMID 31599001, PMID 32816215, PMID 33684552, PMID 35792493, PMID 36342120, PMID 36526796, PMID 36931693, PMID 38425446, PMID 39778975, PMID 25996351, PMID 32635680, PMID 32766762, PMID 32870265, PMID 32964215, PMID 33127596, PMID 33324993, PMID 33513294, PMID 34614208, PMID 35380664, PMID 35380740, PMID 36150926, PMID 36208720, PMID 36336750, PMID 37224198, PMID 37402275, PMID 37560161, PMID 38096402, PMID 38310565, PMID 38778549, PMID 41264726, PMID 41763462, PMID 42248437, PMID 16339095, PMID 19596014, PMID 23648372, PMID 25173754, PMID 25857665

NIH funding

2023 (51), 2017 (42), 2016 (30), 2025 (26), 2014 (25), 2018 (25), 2015 (22), 2019 (22), 2008 (9), 2009 (8), 2004 (6), 2005 (4), K12TR004411 (2), K24DK078228 (2), P30CA060553 (2)